Salute e Benessere

Endo Reports Fourth-Quarter and Full-Year 2024 Financial Results

Separately, the Company announced that it has entered into a definitive agreement to combine with Mallinckrodt plc in a cash and stock transaction. Separately, the Company announced that it has entered into a definitive agreement to combine withMallinckrodtplc in a cash and stock transaction. ENDOFOURTH-QUARTER FINANCIAL PERFORMANCE (in thousands) CONSOLIDATED RESULTS Total revenues in fourth-quarter 2024 were$467 million, a decrease of 6% compared to$498 millionin...
PR Newswire
13/03/2025

ITM Announces Updates to Commercial Leadership

Dr. Sebastian Marx, ITM's chief business officer and member of the Executive Board, is stepping down effective July 20, 2025 after nearly two decades at the company Roger Estafanos, currently U.S. general manager and executive vice president, will be appointed Executive Vice President, Global Head of RadiopharmaceuticalsAlexander Pironi, currently Senior Vice President, will be named Executive Vice President, Global Head of RadioisotopesNew leadership structure aligns with ITM's...
Nasdaq GlobeNewswire
13/03/2025

Spineart and eCential Robotics announce FDA clearance of PERLA® App for use with…

FOR IMMEDIATE RELEASESpineart and eCential Roboticsannounce FDA clearance of PERLA® App for use with Op.nTM robotic navigation platform Dallas, Texas and Franklin, Tennessee, March 13, 2025 — Spineart, a fast-growing company in spine surgery innovation, and eCential Robotics, an expert company in surgical robotics, proudly announce the 510(k) clearance from the U.S. Food and Drug Administration (FDA) of the Spineart PERLA® TL application (PERLA® App) for use with the new eCential...
Nasdaq GlobeNewswire
13/03/2025

IFPA Forum Americas 2025: "Towards More Equitable, Person-Centered Care for All…

The Forum will also explore psoriatic disease within the broader framework ofnon-communicable diseases (NCDs), emphasizing its profound impact on individuals and society. Highlighting the Challenges of Psoriatic Disease Psoriatic disease is a chronic, immune-mediated inflammatory condition that imposes significant physical, emotional, and financial burdens on millions worldwide. According to theGlobal Psoriasis Atlas, its prevalence in the Americas ranges from 0...
PR Newswire
13/03/2025

Caliber Launches 4 Analytics and AI-driven Solutions to Revolutionize Pharma…

"Throughout our 23 years, we have built future-driven products that add immense value to the industry, and even in the current evolving technological landscape, we continue to stay ahead with solutions that help companies to address the challenging regulatory, technology, and economic landscapes," said Sekhar Surabhi, CEO and Founder, Caliber, also the Chair of ISPE India's Pharma 4.0 Community of Practice (CoP). "Throughout our 23 years, we have built future-driven products that…
PR Newswire
13/03/2025

Rxulti® (brexpiprazole) approved in the European Union for the treatment of…

Andy Hodge, CEO at Otsuka Pharmaceutical Europe, said: "The prognosis for adolescence-onset schizophrenia is poor compared with adult-onset schizophrenia and can be associated with more chronic and severe symptoms. We welcome the EC decision to extend the indication for brexpiprazole to include adolescents aged 13 years and older, providing young people in Europe with another much-needed treatment option." Andy Hodge, CEO at Otsuka Pharmaceutical Europe, said: "The prognosis…
PR Newswire
13/03/2025

Tackling the Silent Epidemic: World Kidney Day 2025 Shines Light on Early…

On March 13, 2025, global initiatives will unite under the World Kidney Day (WKD) theme "Are Your Kidneys OK? Detect early, protect kidney health". The 2025 campaign aims to raise awareness about kidney disease risk factors and emphasize the importance of early detection. On March 13, 2025,global initiatives will unite under the World Kidney Day (WKD) theme "Are Your Kidneys OK? Detect early, protect kidney health" . The 2025 campaign aims to raise awareness about kidney…
PR Newswire
13/03/2025

Pioneering plant microbiome research: Julia Vorholt receives 2025 Novonesis…

But how do these microbial communities work? And can we harness their power to make agriculture more sustainable? These questions have driven Professor Julia Vorholt's groundbreaking research work, which has now earned her the 2025 Novonesis Biotechnology Prize, awarded by the Novo Nordisk Foundation. But how do these microbial communities work? And can we harness their power to make agriculture more sustainable? These questions have driven ProfessorJulia Vorholt'sgroundbreaking research...
PR Newswire
13/03/2025

LIfT BioSciences Secures Another Landmark US Patent, Strengthening Its Position…

LIfT BioSciences Secures Another Landmark US Patent, Strengthening Its Position as the World Leader in Neutrophil ImmunotherapiesLondon, 13 March 2025 –LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, has been granted another pivotal patent, further reinforcing its leadership in innate immune-based cell therapies andin vivoimmune modulation.LIfT's newly granted US patent (US 12,070,473 B2) secures...
Nasdaq GlobeNewswire
13/03/2025

Pharming Group reports fourth quarter and full year 2024 financial results and…

Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong Joenja® (leniolisib) growth Fourth quarter 2024 total revenues increased by 14% to US$92.7 million, compared to the fourth quarter 2023RUCONEST® full year revenue increased by 11% to US$252.2 million and fourth quarter revenue increased by 9% to US$79.6 million, compared to the fourth quarter 2023Joenja® revenue increased by 147% to US$45...
Nasdaq GlobeNewswire
13/03/2025

Avextra Unveils Promising Study Results at Major Pain Congress

New Data Highlights Superior Efficacy and Tolerability of Avextra 10/10 in Treating Chemotherapy-Induced Neuropathic PainNews ReleaseBensheim, Germany – 13 March 2025 –At its annual congress in Frankfurt, Germany, this week, researchers from the German Pain Association will be presenting the results of the retrospective register study OCEAN-R, supported by Avextra Pharma, a pioneering German biotech focused on the research and development of Cannabis-Based Medicines (CBMs)...
Nasdaq GlobeNewswire
13/03/2025

Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating…

REGULATED INFORMATIONNyxoah ReportsFourthQuarter and FinancialYear 2024Financial and OperatingResults FDA PMA Application Review Nearing Conclusion Positioned for U.S. Commercial Launch inMarch 2025Mont-Saint-Guibert, Belgium –March 13 , 2024 , 7:00am CET / 2:00am ET– NyxoahSA (Euronext Brussels/Nasdaq:...
Nasdaq GlobeNewswire
13/03/2025

Telix Adds Lead-212 Isotope Production Capability

The novel technology opens new opportunities for the development of alpha-emitting radiopharmaceuticals for use in Telix's next-generation therapeutics pipeline. Lead-212 is a promising isotope for Targeted Alpha Therapy (TAT) but its relatively short half-life (10.6 hours, compared with 9.9 days for actinium-225, 225Ac) and lack of production scale has limited commercial potential. The alpha-emitting profile of 212Pb also has practical synergies with engineered antibodies being developed using…
PR Newswire
13/03/2025

Psoriatic Arthritis Market Sees Major Shift with Growing Biosimilar Adoption |…

As per DelveInsight analysis, among the 7MM, the United States accounted for the highest number of prevalent cases of psoriatic arthritis in 2023, and these cases are expected to increase by the end of 2034 due to several key factors such as an increase in awareness and diagnosis, as well as the rapid prevalence of PsA. As per DelveInsight analysis, among the 7MM,the United Statesaccounted for the highest number of prevalent cases of psoriatic arthritis in 2023, and these cases are expected...
PR Newswire
12/03/2025

ROZLYTREK's Market Growth Reflects Transforming Treatment for NTRK and…

Roche's ROZLYTREK (entrectinib) Overview Roche's ROZLYTREK (entrectinib) Overview ROZLYTREK is a tumor-agnostic therapy that introduces a novel approach to cancer treatment. Its active ingredient, entrectinib, inhibits tropomyosin receptor tyrosine kinases (TRKA, TRKB, and TRKC), which are encoded by the NTRK1, NTRK2, and NTRK3 genes. It also targets ROS1 and ALK, with IC50 values ranging from 0.1 to 2 nM, while showing weaker inhibition of JAK2 and TNK2 (IC50 > 5 nM). The primary...
PR Newswire
12/03/2025

Transactions with shares and linked securities in Genmab A/S made by managerial…

Company Announcement COPENHAGEN, Denmark; March 12, 2025 –Genmab A/S(Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish...
Nasdaq GlobeNewswire
12/03/2025

Global Markets for 3D Cultures and Organoids: Trends Analysis with Forecast

This report explores the global market for laboratory animal models, 3D cultures and organoids, covering major companies, trends, and regional markets. It provides market data from 2023, forecasts through 2029, and analyzes market drivers, restraints, opportunities, and regulatory factors. The report segments the market by type, application, end user, and regions, and analyzes the leading companies and their market shares. This report explores the global market for laboratory animal models…
PR Newswire
12/03/2025

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock…

Company Announcement COPENHAGEN, Denmark; March 12, 2025 –Genmab A/S(Nasdaq: GMAB) Following Genmab A/S' Annual General Meeting held on March 12, 2025, the Company's Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant 13,926 restricted stock units to members of the Board of Directors and employees of the Company and the Company's subsidiaries and 4,214 warrants to the...
Nasdaq GlobeNewswire
12/03/2025

Casino Groupe: Release of the 2024 consolidated financial statements

RELEASE OF THE 2024 CONSOLIDATED FINANCIAL STATEMENTS The Group has released its 2024 consolidated financial statements, in French, on its website. It is available following this link: https://www.groupe-casino.fr/wp-content/uploads/2025/03/Etats-financiers-consolides-2024.pdfAnalyst and investor contactsCharlotte Izabel +33 (0)6 89 19 88 33 [email protected] Relations +33 (0)1 53 65 24 [email protected] Press...
Nasdaq GlobeNewswire
12/03/2025

EUROBIO SCIENTIFIC INCREASES ITS FOOTPRINT IN ITALY

EUROBIO SCIENTIFIC INCREASES ITS FOOTPRINT IN ITALYSigning of the acquisition of Life Science unit of Voden Medical Instruments SpaCompletion of the acquisition of Quimark SRLDecision of supplier T2 Biosystems to stop manufacturing and services its productsParis, March 12, 2025 – 5:35 pmEurobio Scientific(FR0013240934, ALERS), (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro specialty medical diagnostics and life sciences, today announces the...
Nasdaq GlobeNewswire
12/03/2025

Urolithin A Market Grows Strongly with Rising Demand for Anti-Aging and Health…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-33W18171/Global_Urolithin_A_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-33W18171/Global_Urolithin_A_Market Major Factors Driving the Growth of Urolithin A Market: The Urolithin A market continues to expand as scientific research validates its health benefits and commercial applications diversify. Increasing investments in R&D, strategic partnerships, and...
PR Newswire
12/03/2025

Urinary Incontinence Devices Market worth US$7.97 billion by 2030 with 14.5%…

Browse in-depth TOC on "Urinary Incontinence Devices Market"287 - Tables51 - Figures290 - Pages Browse in-depth TOC on "Urinary Incontinence Devices Market" 287 - Tables 51 - Figures 290 - Pages By Based on product type,the urinary incontinence devices market is segmented into urinary catheters, vaginal & urethral slings, electrical stimulation devices, artificial urinary sphincters, and other urinary incontinence devices. Among these, in 2023, the urinary catheters...
PR Newswire
12/03/2025

CBD-infused Products Market to Reach $291.39 Billion by 2032--Exclusive Report…

Download FREE PDF Brochure of CBD-infused Products Market Report - https://www.meticulousresearch.com/download-sample-report/cp_id=5184 Download FREE PDF Brochure of CBD-infused Products Market Report -https://www.meticulousresearch.com/download-sample-report/cp_id=5184 The CBD-infused products market is experiencing robust growth driven primarily by increasing consumer demand for cannabis products, expanding legalization across various jurisdictions, and growing popularity of...
PR Newswire
12/03/2025

xTool Unveils Next Generation Apparel Printer, Surpasses $1 Million on…

Market research revealed three main pain points in traditional DTF printing: complex setup, limited fabric compatibility, and demanding maintenance. "Our users love apparel printing but are frustrated by existing options," said Jasen Wang, founder and CEO of xTool. "With the xTool Apparel Printer, anyone can create custom apparel instantly—just like printing a document at home." The printer addresses these issues with one-click operation and works on cotton, leather…
PR Newswire
12/03/2025
Altri  Comunicati